How Much Weight Should I Lose on Zepbound: An In-Depth Exploration

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no number that answers this question for you personally, and any page that gives you one is guessing. What the evidence provides instead is a distribution: in the pivotal obesity trial of tirzepatide, average weight change at 72 weeks ranged from −15.0% to −20.9% depending on dose, against −3.1% with placebo — but those are group averages, and individual results within each arm spanned a very wide range. The more useful framing is not "how much should I lose" but "what does the evidence say is typical, what threshold do clinicians actually care about, and what happens after."

What the Pivotal Trial Found

SURMOUNT-1 was a phase 3 double-blind randomized trial in 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes. Participants received once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks including a 20-week dose-escalation period. Mean baseline body weight was 104.8 kg.

Mean percentage weight change at week 72 was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg, versus −3.1% with placebo. The responder figures matter more than the averages for anyone trying to calibrate expectations: 85%, 89%, and 91% of participants across the three doses achieved a reduction of 5% or more, compared with 35% on placebo. At the higher bar, 50% of the 10 mg group and 57% of the 15 mg group achieved a reduction of 20% or more, against 3% on placebo.

Read that carefully. Even at the highest dose studied, roughly 9% of participants did not reach 5%, and just under half did not reach 20%. Both of those groups were still in the trial, still taking the medication, and still described by the same headline average.

The 5% Threshold Is the One Clinicians Actually Use

The number that shows up as a coprimary endpoint in these trials is not 20%. It is 5%. That is because a reduction of roughly 5% of body weight is where measurable improvements in cardiometabolic risk factors begin to appear consistently, and regulators and clinicians have long treated it as the point at which a weight-management intervention is doing clinically meaningful work.

SURMOUNT-1 reported improvements in all prespecified cardiometabolic measures with tirzepatide. A benchmark set by social media rather than by trial endpoints is probably calibrated far above where clinical benefit starts.

Head-to-Head Context

In SURMOUNT-5, a phase 3b open-label controlled trial, 751 adults with obesity but without type 2 diabetes were randomized to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) once weekly for 72 weeks. Least-squares mean percent weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide, with waist circumference changes of −18.4 cm and −13.0 cm respectively.

That establishes relative average efficacy between two drugs. It does not set a personal target, because it says nothing about where within either distribution any individual falls, and it excluded people with type 2 diabetes entirely.

Time Is Part of the Answer

Both pivotal trials ran 72 weeks, and SURMOUNT-1 included a 20-week dose-escalation period at the front of that. The figures people quote are endpoint figures from nearly a year and a half of continuous treatment, not milestones from the first few months.

This is where expectations most often break. Judging a response at week 6 or week 12 means judging it during escalation, before a maintenance dosage has even been reached. The Zepbound prescribing information sets a starting dosage of 2.5 mg once weekly for the first four weeks and describes maintenance dosages of 5 mg, 10 mg, or 15 mg once weekly for weight reduction, with a maximum of 15 mg. How quickly any individual moves through those steps is a prescriber judgment based on response and tolerability.

What the Label Is Actually Asking For

The Zepbound indication is worth reading literally: in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. It also carries an indication to treat moderate to severe obstructive sleep apnea in adults with obesity.

"Maintain weight reduction long term" is not a footnote. It reframes the whole question — the goal encoded in the approval is a sustained reduction, not a peak number reached and then left behind.

What Happens If Treatment Stops

SURMOUNT-4 tested this directly. Participants received tirzepatide at the maximum tolerated dose of 10 mg or 15 mg during a 36-week lead-in, then were randomized 1:1 to continue tirzepatide or switch to placebo through week 88. Those who switched to placebo regained substantial weight, while continued treatment produced additional reduction.

A post hoc analysis in JAMA Internal Medicine examined 308 participants who had achieved 10% or greater reduction at week 36 and were switched to placebo, grouped by how much of their lost weight they regained by week 88. Cardiometabolic measures tracked the regain closely: mean waist circumference change from week 36 to week 88 rose across regain categories from 0.8 cm in those regaining less than 25% of their loss, to 5.4 cm, 10.1 cm, and 14.7 cm in the successively higher categories, with systolic blood pressure following the same gradient.

The clinical reading is not that the drug failed, but that obesity behaves as a chronic condition: the improvements are contingent on continued treatment, as blood pressure improvements are contingent on continued antihypertensive therapy.

Why "Should" Is the Wrong Verb

A target belongs to a treatment plan, and a treatment plan belongs to a clinician who knows your starting weight, your comorbidities, your other medications, your prior weight history, and what you are actually trying to improve. Someone treating obstructive sleep apnea, someone managing blood pressure, and someone with a strictly cosmetic goal are not working toward the same endpoint.

Bring the trial distributions into that conversation as context, not as a quota. The question worth asking your prescriber is what change would represent meaningful progress given your specific clinical picture — and how progress will be measured beyond the scale.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight did people lose on tirzepatide in the trials?

In SURMOUNT-1, a 72-week trial in 2,539 adults with obesity or overweight with a complication and without diabetes, mean weight change was −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg, versus −3.1% with placebo. Reductions of 5% or more were achieved by 85% to 91% across the three doses. These are group averages from a controlled trial, not predictions for any individual.

What counts as a good result?

Clinically, the threshold that matters most is lower than most people assume. A reduction of about 5% of body weight is the coprimary endpoint used in these trials, because that is roughly where consistent improvements in cardiometabolic risk factors begin to appear. SURMOUNT-1 reported improvements across all prespecified cardiometabolic measures. What counts as good for you specifically is a judgment for your prescriber.

How long does it take to see results?

The published figures are endpoint results at 72 weeks, and SURMOUNT-1 included a 20-week dose-escalation period before that. The Zepbound label starts dosing at 2.5 mg once weekly for four weeks before any maintenance dosage is reached. Assessing your response in the first weeks means assessing it mid-escalation, which is why timelines should be discussed with the prescriber managing your treatment.

Will I regain the weight if I stop?

SURMOUNT-4 addressed this. After 36 weeks of tirzepatide, participants were randomized to continue or switch to placebo through week 88; those switched to placebo regained substantial weight, while continued treatment produced further reduction. A post hoc analysis found waist circumference and systolic blood pressure worsened in proportion to how much weight was regained, consistent with obesity behaving as a chronic condition.

Is tirzepatide more effective than semaglutide?

In SURMOUNT-5, 751 adults with obesity and without type 2 diabetes received maximum tolerated doses of either drug once weekly for 72 weeks. Least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, with greater waist circumference reduction as well. That is an average across a trial population under one protocol, and it does not establish which medication is appropriate for a particular person.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.